非小细胞肺癌患者血浆中lncRNAMALAT1和lncRNAATB的表达及诊断价值

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1627 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To evaluate the clinical value of plasma lncRNAmetastasisassociated lung adenocarcinoma transcript 1(MALAT1) and lncRNAactivated by TGFβ(ATB) in the diagnosis of nonsmall cell lung cancer (NSCLC). Methods: Quantitative realtime PCR was used to detect the expression level of lncRNAMALAT1 and lncRNA-ATB in plasma samples of 60 patients with NSCLC and 60 patients with benign lung disease. The potential correlations between plasma lncRNAMALAT1 and lncRNA-ATB levels and clinical pathological characteristics in NSCLC patients were analyzed. Receiver operating characteristic curves (ROC) was plotted by statistical software, and area under the curve (AUC) was used to assess the performance of plasma lncRNA-MALAT1 and lncRNAATB in diagnosis of NSCLC. These two performances then were compared with those of serum carcinoembryonic antigen (CEA) and cytokeratin-19fragment (Cyfra211). Results: Compared to benign lung disease patients, the plasma levels of lncRNA-MALAT1 was greatly decreased(P<0.05) and lncRNA-ATB was increased significantly(P<0.05) in NSCLC patients. The plasma levels of lncRNA-MALAT1 and lncRNA-ATB in NSCLC patients were not correlated with gender, age, smoking index, histopathological type and tumor TNM stage(P>0.05). The ROC curves illustrated that AUCs of lncRNA-MALAT1 and lncRNA-ATB was higher than those of CEA and Cyfra21-1. Moreover, the combination of lncRNA-MALAT1 and lncRNA-ATB yielded a higher accuracy as compared to lncRNA-MALAT1 or lncRNAATB alone. Conclusion: Plasma lncRNAMALAT1 and lncRNA-ATB could be used as biomarkers for diagnosis of NSCLC.

Received: 24 November 2018

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LV Meng-jia1
	LI Jian1
	CHEN Ping1
	WANG Ning-xin1
	WANG Yi2

Cite this article:

LV Meng-jia1,LI Jian1,CHEN Ping1等.

#br# Diagnostic value of plasma lncRNA-MALAT1 and lncRNA-ATB levels in non-small cell lung cancer

[J]. Journal of Jiangsu University(Medicine Edition), 2020, 30(02): 160-164.

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2020/V30/I02/160

［1］Ji P, Diederichs S, Wang W, et al. MALAT1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in earlystage nonsmall cell lung cancer\[J\]. Oncogene, 2003, 22（39）:8031-8041.

［2］Hu X, Bao J, Zhen W, et al. The plasma lncRNA acting as fingerprint in nonsmallcell lung cancer\[J\]. Tumor Biol, 2016, 37(3):3497-3504.

［3］Tarro G, Perna A, Esposito C. Early diagnosis of lung cancer by detection of tumor liberated protein\[J\]. J Cell Physiol, 2005, 203（1）:1-5.

［4］Fatica A, Bozzoni I. Long noncoding RNAs: new players in cell differentiation and development\[J\]. Nat Rev Genet, 2014, 15(1):7-21.

［5］Esteller M. Noncoding RNAs in human disease\[J\]. Nat Rev Genet, 2011, 12(12):861-874.

［6］Tano K, Akimitsu N. Long noncoding RNAs in cancer progression\[J\]. Front Genet, 2012, 3:219.

［7］郑红艳, 李加桩, 鲍永霞, 等. lncRNA: 非小细胞肺癌诊断治疗的新策略\[J\]. 中国肿瘤, 2017, 26(4):272-278.

［8］Gibb EA, Brown CJ, Lam WL. The functional role of long noncoding RNA in human carcinomas\[J\]. Mol Cancer, 2011, 10：38.

［9］Tang J, Jiang R, Deng L, et al. Circulation long noncoding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma\[J\]. Oncotarget, 2015, 6（6）:4505-4515.

［10］Arita T, Ichikawa D, Konishi H, et al. Circulating long noncoding RNAs in plasma of patients with gastric cancer\[J\]. Anticancer Res, 2013, 33（8）:3185-3193.

［11］Crea F, Watahiki A, Quagliata L, et al. Identification of a long noncoding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer\[J\]. Oncotarget, 2014, 5（3）:764-774.

［12］Guo F, Fang YU, Wang J, et al. Expression of MALAT1 in the peripheral whole blood of patients with lung cancer\[J\]. Biomed Rep, 2015, 3(3):309-312.

［13］Weber DG, Johnen G, Casjens S, et al. Evaluation of long noncoding RNA MALAT1 as a candidate bloodbased biomarker for the diagnosis of nonsmall cell lung cancer\[J\]. BMC Res Notes, 2013, 6:518.

［14］Li J, Li Z, Zheng W, et al. lncRNAATB: An indispensable cancerrelated long noncoding RNA\[J\]. Cell Proliferation, 2017, 47(1):95-102.

［15］Ke L, Xu SB, Wang J, et al. High expression of long noncoding RNA ATB indicates a poor prognosis and regulates cell proliferation and metastasis in nonsmall cell lung cancer\[J\]. Clin Transl Oncol, 2017, 19(5):1-7.

［16］徐丹, 李军川. 肺腺癌组织和血清中lncRNAATB表达及临床意义分析\[J\]. 临床肿瘤学杂志, 2016, 21(3):218-222.

［17］Schmidt LH, Spieker T, Koschmieder S, et al. The Long noncoding MALAT1 RNA indicates a poor prognosis in nonsmall cell lung cancer and induces migration and tumor growth\[J\]. J Thorac Oncol, 2011, 6(12):1984-1992.

［18］Kogure T, Yan IK, Lin WL, et al. Extracellular vesiclemediated transfer of a novel long noncoding RNA TUC339: A mechanism of intercellular signaling in human hepatocellular cancer\[J\]. Gene Cancer, 2013, 4(7-8):261-272.

［19］Tani H, Nakamura Y, Ijiri K, et al. Stability of MALAT1, a nuclear longcoding RNA in mammalian cells, varies in various cancer cells\[J\]. Drug Discov Ther, 2010, 4(4):235-239.

［20］Ren S, Wang F, Shen J, et al. Long noncoding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasmabased biomarker for diagnosing prostate cancer\[J\]. Eur J Cancer, 2013, 49(13):2949-2959.

［21］Lai MC, Yang Z, Zhou L, et al. Long noncoding RNA MALAT1 overexpression predicts recurrence of hepatocellular carcinoma after liver transplantion\[J\]. Med Oncol, 2012, 29(3):1810-1816.